Baird Medical Showcases Advanced Microwave Ablation Technology at the 2025 ACS Clinical Congress
Baird Medical (NASDAQ: BDMD) is exhibiting at the American College of Surgeons Clinical Congress 2025 in Chicago from October 5–7, 2025. The company is at Booth 1061 presenting live, hands-on demonstrations of its minimally invasive Microwave Ablation (MWA) devices. Demonstrations highlight precision and efficiency for treating thyroid nodules, breast disease, and liver cancer, and aim to engage surgeons and clinical leaders on expanding MWA applications in interventional medicine. Participation underscores Baird Medical's focus on clinical collaboration and advancing patient care through its MWA technology.
Baird Medical (NASDAQ: BDMD) è in mostra al Clinical Congress 2025 dell'American College of Surgeons a Chicago dal 5 al 7 ottobre 2025. L'azienda è allo Stand 1061 e presenta dimostrazioni dal vivo e pratiche dei suoi dispositivi di ablazione a microonde MWA. Le dimostrazioni evidenziano precisione ed efficienza nel trattamento di noduli tiroidei, malattie della mammella e cancro al fegato e mirano a coinvolgere chirurghi e leader clinici nell'espandere le applicazioni MWA nella medicina interventistica. La partecipazione sottolinea l'impegno di Baird Medical nella collaborazione clinica e nel progresso della cura del paziente attraverso la sua tecnologia MWA.
Baird Medical (NASDAQ: BDMD) se presenta en el Clinical Congress 2025 del American College of Surgeons en Chicago del 5 al 7 de octubre de 2025. La empresa se encuentra en el Stand 1061 presentando demostraciones en vivo y prácticas de sus dispositivos de ablación por microondas MWA. Las demostraciones destacan precisión y eficacia para el tratamiento de nódulos tiroideos, enfermedad de la mama y cáncer de hígado, y buscan involucrar a cirujanos y líderes clínicos para ampliar las aplicaciones de la MWA en la medicina intervencionista. La participación subraya el enfoque de Baird Medical en la colaboración clínica y en avanzar en la atención al paciente a través de su tecnología MWA.
베어드 메디컬(NASDAQ: BDMD)은 시카고에서 열리는 American College of Surgeons Clinical Congress 2025에 2025년 10월 5–7일 동안 전시합니다. 회사는 부스 1061에서 최소 침습적 마이크로파 절제 장치 MWA의 실시간 실연 시연을 선보이고 있습니다. 시연은 갑상선 결절, 유방 질환, 간암 치료의 정밀성과 효율성을 강조하며, 외과의와 임상 리더를 대상으로 인터벤셔널 의학에서 MWA 적용을 확장하려는 노력을 목표로 합니다. 참여는 MWA 기술을 통한 임상 협력과 환자 치료 개선을 향한 베어드 메디컬의 초점을 강조합니다.
Baird Medical (NASDAQ: BDMD) est exposant au Clinical Congress 2025 de l'American College of Surgeons à Chicago du 5 au 7 octobre 2025. L'entreprise est au stand 1061 et présente des démonstrations en direct et pratiques de ses appareils d'ablations par micro-ondes MWA. Les démonstrations mettent en évidence la précision et l'efficacité dans le traitement des nodules thyroïdiens, des maladies mammaires et du cancer du foie, et visent à engager les chirurgiens et les leaders cliniques pour élargir les applications de la MWA en médecine interventionnelle. La participation souligne l'accent mis par Baird Medical sur la collaboration clinique et l'amélioration des soins aux patients grâce à sa technologie MWA.
Baird Medical (NASDAQ: BDMD) stellt am Clinical Congress 2025 des American College of Surgeons in Chicago vom 5. bis 7. Oktober 2025 aus. Das Unternehmen ist am Stand 1061 und präsentiert LIVE-Demonstrationen seiner minimal-invasiven Mikrowellen-Ablationsgeräte MWA. Die Demonstrationen heben Präzision und Effizienz bei der Behandlung von Schilddrüsenknoten, Brustkrankheiten und Leberkrebs hervor und zielen darauf ab, Chirurgen und klinische Führungskräfte dazu zu bewegen, die MWA-Anwendungen in der interventionellen Medizin zu erweitern. Die Teilnahme unterstreicht den Fokus von Baird Medical auf klinische Zusammenarbeit und die Verbesserung der Patientenversorgung durch seine MWA-Technologie.
بيارد ميديكال (ناسداك: BDMD) تعرض في مؤتمر Clinical Congress 2025 التابع لجامعة الجراحين الأمريكا في شيكاغو من 5 إلى 7 أكتوبر 2025. تقف الشركة في الجناح 1061 وتقدم عروضاً حية وتطبيقية لأجهزتها الأقل توغلاً في التدخلات باستخدام الإذابة بالموجات الدقيقة MWA. تسلط العروض الضوء على الدقة والكفاءة في علاج عقد الغدة الدرقية، وأمراض الثدي، وسرطان الكبد، وتهدف إلى إشراك الجراحين وقادة الرعاية السريرية في توسيع تطبيقات MWA في الطب التدخلي. المشاركة تؤكد تركيز Baird Medical على التعاون السريري وتحسين رعاية المرضى من خلال تقنيتها MWA.
Baird Medical (纳斯达克: BDMD) 正在芝加哥举行的美国外科医师学院临床大会 Clinical Congress 2025 展示，时间为 2025 年 10 月 5 日至 10 月 7 日。公司在 展位 1061 演示其微创的微波消融 MWA 设备的现场示范。演示强调在治疗甲状腺结节、乳腺疾病和肝癌方面的精准性与效率，旨在吸引外科医生和临床领导者参与，将 MWA 应用扩展到介入医学中。此次参与凸显 Baird Medical 在临床合作与通过其 MWA 技术提升患者护理方面的关注。
- None.
- None.
The ACS, established in 1913, is the world's largest and most influential organization for surgeons, boasting more than 90,000 members across 144 countries. The annual Clinical Congress serves as a key platform for discussing surgical advancements, exploring new technologies, and fostering collaboration within the medical community.
Throughout the congress, Baird Medical is featuring its cutting-edge MWA devices at Booth 1061. The Company is conducting live, hands-on demonstrations showcasing the technology's precision and efficiency in treating a range of conditions, including thyroid nodules, breast disease, and liver cancer. This interactive exhibit provides surgeons and medical professionals the opportunity to experience firsthand the benefits of this minimally invasive treatment modality.
Baird Medical's participation underscores its commitment to collaborating with the surgical community to advance patient care. The Company aims to engage with clinical leaders to discuss the expanding applications of MWA and its role in the future of interventional medicine.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-advanced-microwave-ablation-technology-at-the-2025-acs-clinical-congress-302575470.html
SOURCE BDMD
FAQ
When and where is Baird Medical (BDMD) presenting MWA technology at ACS Clinical Congress 2025?
What MWA procedures is BDMD demonstrating at the October 2025 ACS meeting?
How can surgeons attend BDMD's live demonstrations at ACS Clinical Congress 2025?
What are the expected benefits of BDMD's microwave ablation technology shown at ACS 2025?
Will BDMD discuss clinical applications and future uses of MWA at the ACS 2025 conference?
Is Baird Medical (BDMD) a participant in major surgical conferences beyond ACS Clinical Congress 2025?
